Sonoma Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on June 19, 2019. The report details a corporate action regarding the company's capital structure effective as of 5:00 pm EDT on June 19, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
- Reverse Stock Split: The company implemented a 1-for-9 reverse stock split of its issued and outstanding common stock.
- Trading Adjustment: Common stock (Symbol: SNOA) and warrants (Symbol: SNOAW) began trading on The Nasdaq Capital Market on a 1-for-9 adjusted basis on June 20, 2019.
- Approval Process: The split was approved by stockholders on June 11, 2019, and the ratio was selected by the Board of Directors on June 14, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the execution of the stock split.
Key Facts for Investor Verification
- Verify the adjusted share count and price per share following the 1-for-9 reverse split.
- Confirm the trading status of SNOA and SNOAW on The Nasdaq Capital Market starting June 20, 2019.
- Review the attached Certificate of Amendment (Exhibit 3.1) for specific terms of the capitalization change.